Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs PBF Energy Inc. Class A Common Stock (PBF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs PBF Energy Inc. Class A Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while PBF Energy Inc. Class A Common Stock trades at $89.57 (market cap $10.81B). The key difference: PBF Energy Inc. Class A Common Stock is the larger of the two by market cap, and PBF Energy Inc. Class A Common Stock pays a 1.21% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and PBF Energy Inc. Class A Common Stock for 1 Days on average.
| KYMR | PBF | |
|---|---|---|
Market Cap | $8.87B | $10.81B |
Volume | 779,107 | 3,399,980 |
Sector | Health | Energy |
52-Week High | $127.31 | $91.17 |
52-Week Low | $55.80 | $26.02 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $8.26B | $12.43B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PBF Energy trades at $91.17, up 7.23% in the last 24 hours and near its 52-week high, reflecting strong bullish momentum. The stock shows robust technical strength with a bullish moving average signal and trades above key support levels. Fundamentally, the company is transitioning from a net loss of $158.5 million in 2025 to a projected net profit of $1.4 billion in 2026, driven by restored refinery operations and significant debt reduction. Recent earnings beats, including a Q2 2026 EPS of $6.22 versus $4.15 expected, highlight operational improvements.
The outlook for PBF is positive with strong earnings growth and discounted valuation metrics, but risks include volatile refining margins and geopolitical influences on oil prices. Analyst sentiment is mixed with a consensus price target of $88.75, below the current price, suggesting caution despite the bullish technical setup. Investors should weigh the strong profitability rebound against potential headwinds from energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About PBF Energy Inc. Class A Common Stock
PBF Energy refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics assets supporting its refining business.
Read more on PBF →
